# IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

> **NCT06275893** · PHASE1,PHASE2 · COMPLETED · sponsor: **Implicit Bioscience** · enrollment: 1 (actual)

## Conditions studied

- Arrhythmogenic Right Ventricular Dysplasia
- Arrhythmogenic Left Ventricular Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy 1
- Arrhythmogenic Cardiomyopathy
- ACM
- ARVC
- PKP2

## Interventions

- **BIOLOGICAL:** IC14

## Key facts

- **NCT ID:** NCT06275893
- **Lead sponsor:** Implicit Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-29
- **Primary completion:** 2025-08-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06275893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06275893, "IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06275893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*